A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain

• Published in: Pain (Amsterdam) Vol. 159; no. 9; pp. 1742 - 1751
• Main Authors: Gurrell, Rachel, Dua, Pinky, Feng, Gang, Sudworth, Maria, Whitlock, Mark, Reynolds, David S., Butt, Richard P.
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer 01.09.2018
• Subjects: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Chronic Pain - drug therapy; Double-Blind Method; Female; GABA Modulators - therapeutic use; Humans; Low Back Pain - drug therapy; Male; Middle Aged; Naproxen - therapeutic use; Pain Measurement; Receptors, GABA-A; Treatment Outcome; Young Adult

The effect of PF-06372865, a subtype-selective positive allosteric modulator of the γ-aminobutyric acid type A (GABA A ) receptor, on chronic low back pain was investigated in a randomised, placebo- and active-controlled phase 2 clinical trial. The parallel treatment group trial consisted of a 1-wee...